Please assess the completion status of the following clinical trial:

Trial Title: First Time Use of SD-809 in Huntington Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is at least 18 years of age or the age of majority (whichever is older) at Screening.~* Subject has been diagnosed with manifest HD~* Subject is able to swallow study medication whole.~* Female subjects of childbearing potential agree to use an acceptable method of contraception from screening through study completion.~* The subject has a reliable caregiver who interacts with the patient on a daily basis, oversees study drug administration, assures attendance at study visits and participates in evaluations, as required.~* Subject is able to ambulate without assistance for at least 20 yards (Note: The use of assistive devices (i.e., walker, cane) is permitted during ambulation).~Exclusion Criteria:~* Subject has a serious untreated or under-treated psychiatric illness, such as depression, at Screening or Baseline.~* Subject has active suicidal ideation at Screening or Baseline.~* Subject has history of suicidal behavior at Screening or Baseline:~* Subject has evidence for depression at Screening or Baseline.~* Subject has an unstable or serious medical or psychiatric illness at Screening or Baseline.~* Subject has been recently exposed to tetrabenazine.~* Subject has received any of the following concomitant medications within 30 days of Screening or Baseline:~  * Antipsychotics~ * Metoclopramide~ * Monoamine oxidase inhibitors (MAOI)~ * Levodopa or dopamine agonists~ * Reserpine~ * Amantadine~ * Memantine~* Subject has significantly impaired swallowing function at Screening.~* Subject has significantly impaired speaking at Screening.~* Subject requires treatment with drugs known to prolong the QT interval.~* Subject has a prolonged QT interval on 12-lead ECG at Screening.~* Subject has evidence of hepatic impairment at Screening.~* Subject has evidence of significant renal impairment at Screening.~* Subject has known allergy to any of the components of study medication.~* Subject has participated in an investigational drug or device trial within 30 days (or 5 drug half-lives) of Screening, whichever is longer.~* Subject is pregnant or breast-feeding at Screening or Baseline.~* Subject acknowledges present use of illicit drugs at Screening.~* Subject has a history of alcohol or substance abuse in the previous 12 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SD-809 ER Tablets (Type: EXPERIMENTAL): SD-809 ER tablets are available in three dose strengths: 6, 9 and 12 mg, all of which are identical in size, shape and color (white). All are administered three times a day, with the 6 mg final dose is placebo.
- SD-809 Tablets (Type: EXPERIMENTAL): SD-809 tablets are available in three dose strengths: 6, 9 and 12 mg, all of which are identical in size, shape and color (white). All are administered three times a day, with the 6 mg final dose is placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).